PURPOSE

The purpose of this policy is to describe Institutional Review Board (IRB) oversight required to protect the rights and welfare of human participants who are, or are likely to become, cognitively impaired during the proposed time period of research participation at Beaumont Health (Beaumont).

SCOPE

This policy applies to investigators, key research personnel, IRB members and IRB staff.

BACKGROUND

There are no specific federal regulations concerning the inclusion of cognitively impaired participants in clinical research. These vulnerable participants have the same rights as other individuals to participate in research, but special care must be taken to avoid coercion.

The IRB oversees the protection of the rights and welfare of research participants who are temporarily or permanently cognitively impaired by requiring additional safeguards in study conduct and the informed consent and authorization process.

Some research protocols aim to enroll cognitively impaired individuals as the study population and specifically focus on their special problems. Examples include, but are not limited to, patients with dementia, schizophrenia, delirium, mental retardation, bipolar disorder, or those in a comatose state. Other research protocols may focus on an illness or condition unrelated to cognitive ability but will incidentally include one or more vulnerable participants when an individual with altered cognition meets enrollment criteria and is enrolled in the trial. In either case, special considerations must be made to ensure study conduct and the informed consent and authorization process is adequate and appropriate for the participant’s level of comprehension.

DEFINITIONS

Legally Authorized Representative

A Legally Authorized Representative (LAR) is an individual authorized to consent on behalf of a prospective participant for her/his involvement in research. An LAR may consent on behalf of the participant only when it has been determined the participant does not have the mental capacity to knowingly and willingly make an informed decision, in accordance with Beaumont Corporate Policy 304 Informed Consent.

Legally Authorized Representatives may include, in order of authority:

a) Legal Guardian. A Legal Guardian is appointed by a Probate Court. The Legal Guardian is provided a letter by the Court documenting the scope of authority. A copy of the letter must be in the medical record or provided at the time of consent in order for the guardian to consent for the participant. If provided at the time of consent, the consent provider must make a copy of the letter for the medical and research records. It is the consent provider’s responsibility to confirm guardianship prior to obtaining consent. Once a Legal Guardian is appointed, only the guardian has the authority to provide consent,
b) **Patient advocate pursuant to Durable Power of Attorney (DPOA) for health care.** A DPOA for health care is a written document by which a competent adult patient has given the power to make medical or psychiatric treatment care decisions on behalf of the patient when the patient is unable to participate in treatment decisions. The designated adult is called the patient advocate. If a DPOA is executed and the patient/potential participant is subsequently found to be incompetent, the consent of the patient advocate is necessary for participation in a research study. Before the patient advocate can make treatment or participation decisions for the patient, the patient advocate must sign an Acceptance Form and both the DPOA and the Acceptance Form must be in the participants’ medical record.

c) **Family.** If it is determined a participant is incompetent and there is not a court appointed legal guardian or a DPOA, the next of kin may consent to research participation provided all of the following conditions are met:

- The investigator believes the research treatment should not be delayed until the participant recovers sufficiently to give consent.
- The investigator documents the reason(s) in the participants’ medical and/or research record.
- Neither the physician nor the next of kin knows the participant would be opposed to participating given the specific set of circumstances.

Family members, in order of decreasing authority, include (used only when no court appointed guardian or DPOA for health care exists):

1. Spouse
2. Adult daughter or son
3. Either parent
4. Adult sibling.

**Assent**

An individual’s affirmative agreement to participate in research obtained in conjunction with permission from the individual’s LAR. Mere failure to object should not be construed as assent.

**Cognitively Impaired**

Having a psychiatric disorder (e.g., psychosis, neurosis, personality or behavior disorder), an organic brain syndrome (e.g., stroke, dementia), a developmental disability (e.g., Down syndrome, autism), or a catastrophic event that affects cognitive functioning (e.g., traumatic brain injury, coma) to the extent capacity for judgment and reasoning is temporarily or permanently diminished. Persons under the influence or dependent on drugs or alcohol, those suffering from degenerative diseases affecting the brain, or terminally or critically ill patients, may also be defined as cognitively impaired as their ability to make informed decisions may be affected.
Dissent

An individual’s negative expressions, verbal and/or non-verbal, that they object to participation in the research or research activities.

POLICY

It is the policy of Beaumont to protect the rights of all research participants, including those who may be cognitively impaired. The Beaumont Health IRB serves as the primary Institutional Review Board for human participant research conducted at Beaumont (for information about the use of external IRB’s, see policy 233 Review by Another Institutional Review Board). In accordance with federal regulations, IRB review and approval is required to protect the rights and welfare of human participants. It is the policy of the IRB to review, approve, and provide guidance on special ethical considerations when cognitively impaired participants are involved in research. The IRB will conduct initial and continuing review of each ongoing research trial, at intervals appropriate to the degree of risk to human participants, but at a minimum once per year. Research protocols may aim to enroll cognitively impaired participants as the intended study population or may incidentally enroll cognitively impaired participants. These studies will be reviewed to ensure additional safeguards are incorporated in the protocol and informed consent and authorization process to ensure the risks and benefits are commensurate with research participation.

Determining Mental Capacity

An adult is presumed to be competent. A cognitively impaired adult with limited mental capacity may not understand her/his medical condition, proposed treatments and/or alternative treatments. Cognitively impaired individuals may have diminished autonomy which may limit their capacity to provide or withdraw informed consent and authorization. If mental capacity is questionable, the treating physician should make the appropriate consult to psychiatry, gerontology, etc.

It is the responsibility of the principal investigator (PI), and any authorized consent provider, to assess the individual’s mental capacity at the time of initial consent and authorization, and continually throughout the research study to assure continued protection of the participant’s rights.

When a consent provider determines a potential participant is cognitively impaired, the research consent and authorization must be obtained from the participant’s LAR. The consent provider must document this determination and justification in the medical chart and research record at the time of the consent and authorization procedure. Assent from the participant should be obtained as appropriate and documented in the medical chart and research record.

Changes in Cognitive Status During Research Participation

Additionally, should the participant’s cognitive status change during the course of the study and the participant no longer has the cognitive capacity to provide consent, the consent and authorization of the participant’s LAR must be sought for continued involvement in the study. Any significant communication or interaction key personnel have
with the participant or LAR, related to the participant’s ongoing or newly
developed cognitive impairment, must be documented in the research
record.

Furthermore, should a previously cognitively impaired participant
(enrolled in research through consent of their LAR) recover cognitive
capacity, the participant must be consented, using a clean copy of the
current informed consent and authorization document, to continue
participating in the research.

During review of the research proposal, the IRB must find appropriate
provisions are made for determining a participant’s ability to provide
consent or to withdraw, through evidence of one or more of the
following characteristics pertaining to the individual:
  a. The ability to willingly make a choice.
  b. The ability to understand relevant information.
  c. The ability to appreciate the situation and its likely consequences.
  d. The ability to manipulate information rationally.

Assent Requirements

When utilizing the cognitively impaired participant’s LAR, the
participant’s assent must also be obtained whenever possible. The
decision to obtain assent should include considerations of the risks and
benefits expected from participation in the proposed research, as well as
the ability of the research participant to provide written or oral assent.

All research participants must be informed of all aspects of their research
involvement to the extent possible. The following rules apply to the
requirements for obtaining assent from a potential research participant
who is cognitively impaired:
  a. If there is a reasonable probability of benefit to the participant from
     participation in the research, or there is little direct benefit but
     minimal risk, written assent is not required. The participant’s oral
     assent in addition to the written consent of the LAR would be
     sufficient.
  b. If participation in the research provides no reasonably expected
     benefit to the participant and involves more than minimal risk,
     the cognitively impaired participant’s written assent must be
     obtained in addition to the written consent of the LAR. If the
     cognitively impaired participant cannot provide written assent
     due to their condition, they may not be enrolled in the study.
  c. When a participant is cognitively impaired and their LAR provides
     consent and authorization to enroll the participant in the research, the
     LAR completes the “Alternate Signature” fields on the IRB-approved
     informed consent and authorization document. When the intended
     research population is participants with cognitive impairment and the
     participant is able to provide written assent, the participant should
     sign an IRB-approved, study-specific assent document. An assent
     template is available on the IRB website. If the participant’s
     cognitive impairment was incidental to his/her eligibility for the
study and the participant is able to provide written assent, the participant should sign and/or print on the last page of the informed consent and authorization document, next to the signature of the LAR. The written or oral assent procedure, with consent by the LAR, must be documented in the medical record and research files by the consent provider at the time of the procedure. The witness must be a Beaumont employee.

IRB Submission Requirements for Research Intending to Enroll Cognitively Impaired Participants

When cognitively impaired participants are the intended research population, a study specific assent document should be prepared and submitted for IRB approval. The investigator must provide the IRB with the following:

- Justification for aiming to enroll vulnerable participants.
- A description of any special procedures or circumstances which apply to participant recruitment.
- The method for identifying the participant’s LAR, and the method for obtaining consent and authorization from the LAR.
- The method of obtaining assent from the participant.

These issues are addressed in the initial IRB protocol application within iMedRIS.

In addition, the informed consent and authorization document must include both of the following:

- A signature line for the LAR, with a prompt to designate the basis for the LAR’s authority to sign the informed consent and authorization document (e.g., court appointed guardian, next of kin, patient advocate pursuant to medical Durable Power of Attorney).
- A signature line for a witness.

REFERENCES

21 CFR 50 Subpart B Informed Consent Requirements
21 CFR 56.107(a) IRB Membership
21 CFR 56.108 IRB Functions and Operations
45 CFR 46.111(b) Criteria for IRB Approval and Research
45 CFR 46.108 IRB Functions and Operations
45 CFR 46.116 Requirements for Informed Consent
45 CFR 46.117 Documentation of Informed Consent

The Belmont Report


The Office of Human Subjects Research (OHSR), National Institutes of Health, Information Sheet #7, “Research Involving Cognitively Impaired Subjects: A Review of Some Ethical Considerations”

ASSOCIATED POLICIES

IRB Policy 216 IRB Initial Review of Research Protocols
IRB Policy 221 Informed Consent and Authorization Process
Beaumont Corporate Patient Care Policy 304 Informed Consent